Table of Content


Table of Contents 2
Tables 5
Charts 6
Boehringer Ingelheim International GmbH - Key Company Facts 7
Boehringer Ingelheim International GmbH - Company Description 8
Boehringer Ingelheim International GmbH - Top Executives 9
Boehringer Ingelheim International GmbH - Top Executives Biographies 10
Boehringer Ingelheim International GmbH - Head Office & Locations 12
Head Office - Country 12
Key Subsidiaries 13
Key Joint Ventures 15
Boehringer Ingelheim International GmbH - Products and Services 16
Products 16
Boehringer Ingelheim International GmbH - Historic Events 19
Boehringer Ingelheim International GmbH - Company’s Management Discussion 20
Boehringer Ingelheim International GmbH - Company’s Mission and Vision 22
Vision 22
Boehringer Ingelheim International GmbH - Corporate Strategy 23
Boehringer Ingelheim International GmbH - Business Description 25
Human Pharmaceuticals 25
Animal Health 26
Biopharmaceutical Contract Manufacturing 26
Other Sales 26
Boehringer Ingelheim International GmbH - ESG Spotlight 27
Environment 27
Social 27
Corporate Governance 28
Boehringer Ingelheim International GmbH - SWOT Analysis 29
Overview 29
Strengths 31
Weaknesses 34
Opportunities 35
Threats 38
Boehringer Ingelheim International GmbH - PESTLE Analysis 40
Overview 40
Political Factors 42
Economic Factors 44
Social Factors 45
Technological Factors 47
Legal Factors 49
Environmental Factors 51
Competing Players 52
Snapshot of Competing Players 53
AstraZeneca Plc 53
Key Company Facts 53
Company Description 53
GSK plc 55
Key Company Facts 55
Company Description 55
Novartis AG 57
Key Company Facts 57
Company Description 57
Pfizer Inc. 59
Key Company Facts 59
Company Description 59
Sanofi SA 61
Key Company Facts 61
Company Description 61
Boehringer Ingelheim International GmbH - In the News 63
18-Apr-2024 - Boehringer Ingelheim introduces NexGard SPECTRA for dogs in India 63
09-Apr-2024 - Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets 66
14-Feb-2024 - Jardiance (empagliflozin) now approved in India for the treatment of adults with chronic kidney disease 68
01-Feb-2024 - Boehringer Ingelheim India earns "Top Employer 2024" accolade for second consecutive year 70
20-Sep-2023 - Boehringer Ingelheim India joins forces with Pet Practitioners Association of Mumbai (PPAM) and Brihanmumbai Municipal Corporation (BMC) to ?Stop Rabies’ in Mumbai 72
05-Sep-2023 - New partnership working on solutions to combat African animal trypanosomiasis 74
17-Aug-2023 - Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity 75
14-Aug-2023 - Boehringer Ingelheim receives FDA approval for SENVELGO? (velagliflozin oral solution): the first oral liquid medication for diabetes in cats 76
20-Jul-2023 - Boehringer Ingelheim Receives FDA Approval for NexGard? PLUS (afoxolaner, moxidectin and pyrantel chewable tablets): A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites 76
09-May-2023 - Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases 79
24-Apr-2023 - Boehringer Ingelheim inaugurates largest European development centre for biotechnology 81
29-Mar-2023 - Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth 83
19-Dec-2022 - Boehringer Ingelheim and Click Therapeutics expand their existing Collaboration to develop Prescription Digital Therapeutics for Schizophrenia 85
06-Sep-2022 - Boehringer Ingelheim launches Fencovis?, a new vaccine to prevent calf diarrhea 87
14-Jun-2022 - Boehringer Ingelheim and CarthroniX announce partnership to pursue small molecule therapeutics in canine oncology 88
Boehringer Ingelheim International GmbH - Key Deals 89
14-Jun-2022 - Boehringer Ingelheim signs Option to Acquire Trutino Biosciences 89
Appendix 91
Definitions 91
SWOT Analysis 91
PESTLE Analysis 91
Value Chain Analysis 91
ESG Spotlight 91
Research Methodology 92
Disclaimer 93
Contact Us 93



List of Figures

Charts

Figure 1: Boehringer Ingelheim International GmbH - SWOT Analysis 30
Figure 2: Boehringer Ingelheim International GmbH - PESTLE Analysis 41
Figure 3: Competing Players - AstraZeneca Plc - Key Financials 54
Figure 4: Competing Players - GSK plc - Key Financials 56
Figure 5: Competing Players - Novartis AG - Key Financials 58
Figure 6: Competing Players - Pfizer Inc. - Key Financials 60
Figure 7: Competing Players - Sanofi SA - Key Financials 62

List of Tables

Tables

Table 1: Boehringer Ingelheim International GmbH - Company Facts 7
Table 2: Boehringer Ingelheim International GmbH - Top Executives 9
Table 3: Boehringer Ingelheim International GmbH - Top Executives Biographies 10
Table 4: Boehringer Ingelheim International GmbH - Subsidiaries 13
Table 5: Boehringer Ingelheim International GmbH - Key Joint Ventures 15
Table 6: Boehringer Ingelheim International GmbH - Products 16
Table 7: Boehringer Ingelheim International GmbH - Historic Events 19
Table 8: Boehringer Ingelheim International GmbH - Competing Players 52
Table 9: Competing Players - AstraZeneca Plc - Key Company Facts 53
Table 10: Competing Players - AstraZeneca Plc - Key Financials 54
Table 11: Competing Players - GSK plc - Key Company Facts 55
Table 12: Competing Players - GSK plc - Key Financials 56
Table 13: Competing Players - Novartis AG - Key Company Facts 57
Table 14: Competing Players - Novartis AG - Key Financials 58
Table 15: Competing Players - Pfizer Inc. - Key Company Facts 59
Table 16: Competing Players - Pfizer Inc. - Key Financials 60
Table 17: Competing Players - Sanofi SA - Key Company Facts 61
Table 18: Competing Players - Sanofi SA - Key Financials 62